HIGHLIGHTS
- who: Zi Liu from the (UNIVERSITY) have published the research: An overview of PROTACs: a promising drug discovery paradigm, in the Journal: (JOURNAL)
- what: Collectively the studies provide references for further application of PROTACs. The aim of medicinal chemistry researchers is the discovery of molecules with high selectivity to minimize adverse effects and toxicity brought on by off-target effects. The main reason is that CRBN is widely expressed in tissues with high abundance and CRBN-based PROTACs have better degradation efficiency. Some other E3 ligases such as DCAF11 , DCAF15 , DCAF16 , KEAP1 , and RNF114 etc . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.